Diagnostic Approach to Thrombocytosis
Diagnostic Evaluation
- A complete blood count with reticulocyte count and peripheral blood smear (morfología plaquetaria) is essential for the diagnosis of thrombocytosis 1
Risk Stratification and Management
- The American Society of Clinical Oncology recommends that patients with myeloproliferative neoplasms and high-risk features such as age > 60 years, previous thrombosis, or platelet count > 1,500 × 10^9/L should receive hydroxyurea to reduce the platelet count to < 400 × 10^9/L and low-dose aspirin to prevent thrombotic events 2
- For pregnant patients with myeloproliferative neoplasms, low-dose aspirin and low-molecular-weight heparin during pregnancy, and consideration of interferon alfa if the platelet count is ≥ 1,500 × 10^9/L 2
- Anticoagulation with low-molecular-weight heparin followed by long-term oral anticoagulation, and hydroxyurea to restore platelet counts to 400 × 10^9/L in patients with splenic thrombosis 2